First National Bank of Omaha’s Regeneron Pharmaceuticals REGN Stock Holding History

First National Bank of Omaha’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-293	Closed	-$308K	–	312
2024 Q2	$308K	Buy	+293	New	+$284K	0.02%	280
2024 Q1	–	Sell	-431	Closed	-$379K	–	339
2023 Q4	$379K	Sell	431 -95	-18%	-$78.2K	0.02%	282
2023 Q3	$433K	Sell	526 -591	-53%	-$464K	0.03%	272
2023 Q2	$803K	Sell	1,117 -4,389	-80%	-$3.38M	0.05%	231
2023 Q1	$4.52M	Sell	5,506 -254	-4%	-$192K	0.27%	120
2022 Q4	$4.16M	Sell	5,760 -1,393	-19%	-$1.03M	0.26%	124
2022 Q3	$4.93M	Sell	7,153 -302	-4%	-$190K	0.32%	103
2022 Q2	$4.41M	Sell	7,455 -340	-4%	-$221K	0.27%	117
2022 Q1	$5.44M	Sell	7,795 -13	-0.2%	-$8.22K	0.28%	113
2021 Q4	$4.93M	Sell	7,808 -126	-2%	-$77.5K	0.24%	133
2021 Q3	$4.8M	Sell	7,934 -1,926	-20%	-$1.2M	0.24%	130
2021 Q2	$4.67M	Hold	9,860	–	–	0.24%	133
2021 Q1	$4.67M	Buy	9,860 +1,365	+16%	+$665K	0.24%	133
2020 Q4	$4.1M	Buy	8,495 +160	+2%	+$86.4K	0.22%	137
2020 Q3	$4.67M	Sell	8,335 -171	-2%	-$104K	0.29%	110
2020 Q2	$5.3M	Sell	8,506 -1,300	-13%	-$738K	0.36%	92
2020 Q1	$4.79M	Sell	9,806 -1,694	-15%	-$699K	0.37%	87
2019 Q4	$4.32M	Buy	+11,500	New	+$3.87M	0.26%	128

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

First National Bank of Omaha's REGN Position: Q3 2024 in Review

First National Bank of Omaha sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 293 shares — an estimated $308K sold.

First National Bank of Omaha first reported a position in REGN in Q4 2019 and held it in 18 quarters. The position peaked at $5.44M in Q1 2022. 1,389 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

First National Bank of Omaha reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
First National Bank of Omaha sold 293 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $308K.
First National Bank of Omaha first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 18 quarters.
First National Bank of Omaha's Regeneron Pharmaceuticals position peaked at $5.44M in Q1 2022.
1,389 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on First National Bank of Omaha's 13F filing for Q3 2024, filed 15 Nov 2024.